$CNO
CNO Financial Group, Inc. Stock $cno

$cno Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000122460821000042 Filed on November 04, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$1.075B	$968.3M	$1.014B
YoY Change	-0.13%	-4.46%	7.36%
Cost Of Revenue		$524.8M	$560.7M
YoY Change		-6.4%	-3.79%
Gross Profit		$443.5M	$452.8M
YoY Change		-2.05%	25.36%
Gross Profit Margin		45.8%	44.68%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$903.1M	$816.6M	$823.4M
YoY Change	-0.69%	-0.83%	-3.47%
Operating Profit		$119.3M	$145.3M
YoY Change		-17.89%	65.3%
Interest Expense	-$23.60M	$23.70M	$23.70M
YoY Change	1.29%	0.0%	-36.8%
% of Operating Profit		19.87%	16.31%
Other Income/Expense, Net
YoY Change
Pretax Income	$148.1M	$128.0M	$166.4M
YoY Change	3.21%	-23.08%	211.03%
Income Tax	$32.30M	$28.20M	$37.20M
% Of Pretax Income	21.81%	22.03%	22.36%
Net Earnings	$115.8M	$99.80M	$129.2M
YoY Change	3.58%	-22.76%	207.62%
Net Earnings / Revenue	10.77%	10.31%	12.75%
Basic Earnings Per Share	$0.95	$0.79	$0.92
Diluted Earnings Per Share	$0.93	$0.77	$0.91
COMMON SHARES
Basic Shares Outstanding	123.3M shares	126.4M shares	140.9M shares
Diluted Shares Outstanding		129.0M shares	141.7M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$731.7M	$812.6M	$786.6M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$28.93B	$28.26B	$26.82B
YoY Change	4.87%	5.37%	5.85%
Other Assets	$118.3M	$145.7M	$322.0M
YoY Change	-40.55%	-54.75%	33.06%
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets	$36.20B	$35.71B	$34.57B
YoY Change	2.45%	3.31%	3.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt	$4.001B	$4.030B	$3.785B
YoY Change	1.78%	6.46%	-0.05%
Other Long-Term Liabilities	$830.9M	$995.3M	$856.0M
YoY Change	1.08%	16.27%	12.34%
Total Long-Term Liabilities	$4.832B	$5.025B	$4.641B
YoY Change	1.66%	8.27%	2.02%
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities	$4.832B	$5.025B	$4.641B
Total Liabilities	$30.94B	$30.48B	$29.49B
YoY Change	3.65%	3.38%	2.64%
SHAREHOLDERS EQUITY
Retained Earnings	$1.127B	$1.027B	$657.5M
YoY Change	49.83%	56.26%	139.7%
Common Stock	$2.185B	$2.276B	$2.625B
YoY Change	-14.16%	-13.3%	-7.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.260B	$5.233B	$5.084B
YoY Change
Total Liabilities & Shareholders Equity	$36.20B	$35.71B	$34.57B
YoY Change	2.45%	3.31%	3.87%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	$115.8M	$99.80M	$129.2M
YoY Change	3.58%	-22.76%	207.62%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	$119.3M	$240.7M	$216.8M
YoY Change	-38.41%	11.02%	12.22%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$730.7M	-$245.0M	-$50.20M
YoY Change	309.13%	388.05%	-727.5%
Cash From Investing Activities	-$730.7M	-$245.0M	-$50.20M
YoY Change	309.13%	388.05%	-727.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	530.5M	102.1M	62.10M
YoY Change	178.92%	64.41%	381.4%
NET CHANGE
Cash From Operating Activities	119.3M	240.7M	216.8M
Cash From Investing Activities	-730.7M	-245.0M	-50.20M
Cash From Financing Activities	530.5M	102.1M	62.10M
Net Change In Cash	-80.90M	97.80M	228.7M
YoY Change	-139.41%	-57.24%	6.82%
FREE CASH FLOW
Cash From Operating Activities	$119.3M	$240.7M	$216.8M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001224608
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
CY2019	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-31792
	dei	Entity Registrant Name EntityRegistrantName	CNO Financial Group, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-3108137
	dei	Entity Address Address Line1 EntityAddressAddressLine1	11825 N. Pennsylvania Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Carmel,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46032
	dei	City Area Code CityAreaCode	(317)
	dei	Local Phone Number LocalPhoneNumber	817-6100
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	123313475	shares
CY2021Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	5400000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	2200000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	21151000000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	19921100000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	24142000000	USD
CY2021Q3	cno	Investments Held By Variable Interest Entities InvestmentsHeldByVariableInterestEntities	1221300000	USD
CY2020Q4	cno	Investments Held By Variable Interest Entities InvestmentsHeldByVariableInterestEntities	1189400000	USD
CY2021Q3	us-gaap	Other Investments OtherInvestments	1172600000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	23383600000	USD
CY2021Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	146400000	USD
CY2020Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	151200000	USD
CY2021Q3	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	7300000	USD
CY2020Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	11800000	USD
CY2021Q3	us-gaap	Notes Receivable Net NotesReceivableNet	1211000000	USD
CY2020Q4	us-gaap	Notes Receivable Net NotesReceivableNet	1358700000	USD
CY2021Q3	us-gaap	Policy Loans Receivable PolicyLoansReceivable	119700000	USD
CY2020Q4	us-gaap	Policy Loans Receivable PolicyLoansReceivable	123000000.0	USD
CY2021Q3	us-gaap	Trading Securities Debt TradingSecuritiesDebt	243600000	USD
CY2020Q4	us-gaap	Trading Securities Debt TradingSecuritiesDebt	232000000.0	USD
CY2021Q3	cno	Investments Held By Variable Interest Entities Allowance For Credit Loss InvestmentsHeldByVariableInterestEntitiesAllowanceForCreditLoss	2500000	USD
CY2020Q4	cno	Investments Held By Variable Interest Entities Allowance For Credit Loss InvestmentsHeldByVariableInterestEntitiesAllowanceForCreditLoss	15100000	USD
CY2021Q3	cno	Investments Held By Variable Interest Entities Amortized Cost InvestmentsHeldByVariableInterestEntitiesAmortizedCost	1225300000	USD
CY2020Q4	cno	Investments Held By Variable Interest Entities Amortized Cost InvestmentsHeldByVariableInterestEntitiesAmortizedCost	1211300000	USD
CY2020Q4	us-gaap	Other Investments OtherInvestments	1146400000	USD
CY2021Q3	us-gaap	Investments Investments	28256600000	USD
CY2020Q4	us-gaap	Investments Investments	27584300000	USD
CY2021Q3	cno	Cash And Cash Equivalents At Carrying Value Excluding Variable Interest Entities CashAndCashEquivalentsAtCarryingValueExcludingVariableInterestEntities	742100000	USD
CY2020Q4	cno	Cash And Cash Equivalents At Carrying Value Excluding Variable Interest Entities CashAndCashEquivalentsAtCarryingValueExcludingVariableInterestEntities	937800000	USD
CY2021Q3	cno	Cash And Cash Equivalents Held By Variable Interest Entities CashAndCashEquivalentsHeldByVariableInterestEntities	70500000	USD
CY2020Q4	cno	Cash And Cash Equivalents Held By Variable Interest Entities CashAndCashEquivalentsHeldByVariableInterestEntities	54100000	USD
CY2021Q3	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	218100000	USD
CY2020Q4	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	205800000	USD
CY2021Q3	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	229000000.0	USD
CY2020Q4	us-gaap	Value Of Business Acquired Voba ValueOfBusinessAcquiredVOBA	249400000	USD
CY2021Q3	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1082700000	USD
CY2020Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1027800000	USD
CY2021Q3	us-gaap	Reinsurance Recoverables Allowance ReinsuranceRecoverablesAllowance	4000000.0	USD
CY2020Q4	us-gaap	Reinsurance Recoverables Allowance ReinsuranceRecoverablesAllowance	4000000.0	USD
CY2021Q3	us-gaap	Reinsurance Recoverables On Paid Losses ReinsuranceRecoverablesOnPaidLosses	4409700000	USD
CY2020Q4	us-gaap	Reinsurance Recoverables On Paid Losses ReinsuranceRecoverablesOnPaidLosses	4584300000	USD
CY2021Q3	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	145700000	USD
CY2020Q4	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	199400000	USD
CY2021Q3	us-gaap	Separate Account Assets SeparateAccountAssets	4500000	USD
CY2020Q4	us-gaap	Separate Account Assets SeparateAccountAssets	4200000	USD
CY2021Q3	us-gaap	Other Assets OtherAssets	554800000	USD
CY2020Q4	us-gaap	Other Assets OtherAssets	492800000	USD
CY2021Q3	us-gaap	Assets Assets	35713700000	USD
CY2020Q4	us-gaap	Assets Assets	35339900000	USD
CY2021Q3	us-gaap	Policyholder Funds PolicyholderFunds	12992000000	USD
CY2020Q4	us-gaap	Policyholder Funds PolicyholderFunds	12540600000	USD
CY2021Q3	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	11699700000	USD
CY2020Q4	us-gaap	Liability For Future Policy Benefits LiabilityForFuturePolicyBenefits	11744200000	USD
CY2021Q3	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	512300000	USD
CY2020Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	561800000	USD
CY2021Q3	us-gaap	Unearned Premiums UnearnedPremiums	247500000	USD
CY2020Q4	us-gaap	Unearned Premiums UnearnedPremiums	252600000	USD
CY2021Q3	us-gaap	Separate Accounts Liability SeparateAccountsLiability	4500000	USD
CY2020Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	4200000	USD
CY2021Q3	us-gaap	Other Liabilities OtherLiabilities	995300000	USD
CY2020Q4	us-gaap	Other Liabilities OtherLiabilities	821800000	USD
CY2021Q3	cno	Investment Borrowings InvestmentBorrowings	1741100000	USD
CY2020Q4	cno	Investment Borrowings InvestmentBorrowings	1642500000	USD
CY2021Q3	cno	Borrowings Related To Variable Interest Entities BorrowingsRelatedToVariableInterestEntities	1151400000	USD
CY2020Q4	cno	Borrowings Related To Variable Interest Entities BorrowingsRelatedToVariableInterestEntities	1151800000	USD
CY2021Q3	us-gaap	Notes Payable NotesPayable	1137000000	USD
CY2020Q4	us-gaap	Notes Payable NotesPayable	1136200000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	30480800000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	29855700000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	8000000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	8000000000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124269869	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124269869	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135279119	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	135279119	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	1200000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1300000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2274600000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2544500000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1929700000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2186100000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1027400000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	752300000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	5232900000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5484200000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35713700000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35339900000	USD
CY2021Q3	us-gaap	Premiums Earned Net PremiumsEarnedNet	630600000	USD
CY2020Q3	us-gaap	Premiums Earned Net PremiumsEarnedNet	628300000	USD
	us-gaap	Premiums Earned Net PremiumsEarnedNet	1893500000	USD
	us-gaap	Premiums Earned Net PremiumsEarnedNet	1882300000	USD
CY2021Q3	cno	Net Investment Income On General Account Invested Assets NetInvestmentIncomeOnGeneralAccountInvestedAssets	289500000	USD
CY2020Q3	cno	Net Investment Income On General Account Invested Assets NetInvestmentIncomeOnGeneralAccountInvestedAssets	276900000	USD
	cno	Net Investment Income On General Account Invested Assets NetInvestmentIncomeOnGeneralAccountInvestedAssets	854300000	USD
	cno	Net Investment Income On General Account Invested Assets NetInvestmentIncomeOnGeneralAccountInvestedAssets	788900000	USD
CY2021Q3	cno	Net Investment Income On Policyholder And Reinsurer Accounts And Other Special Purpose Portfolios NetInvestmentIncomeOnPolicyholderAndReinsurerAccountsAndOtherSpecialPurposePortfolios	18700000	USD
CY2020Q3	cno	Net Investment Income On Policyholder And Reinsurer Accounts And Other Special Purpose Portfolios NetInvestmentIncomeOnPolicyholderAndReinsurerAccountsAndOtherSpecialPurposePortfolios	66600000	USD
	cno	Net Investment Income On Policyholder And Reinsurer Accounts And Other Special Purpose Portfolios NetInvestmentIncomeOnPolicyholderAndReinsurerAccountsAndOtherSpecialPurposePortfolios	171300000	USD
	cno	Net Investment Income On Policyholder And Reinsurer Accounts And Other Special Purpose Portfolios NetInvestmentIncomeOnPolicyholderAndReinsurerAccountsAndOtherSpecialPurposePortfolios	43000000.0	USD
CY2021Q3	us-gaap	Debt And Equity Securities Gain Loss Excluding Other Than Temporary Impairment Loss DebtAndEquitySecuritiesGainLossExcludingOtherThanTemporaryImpairmentLoss	-900000	USD
CY2020Q3	us-gaap	Debt And Equity Securities Gain Loss Excluding Other Than Temporary Impairment Loss DebtAndEquitySecuritiesGainLossExcludingOtherThanTemporaryImpairmentLoss	8200000	USD
	us-gaap	Debt And Equity Securities Gain Loss Excluding Other Than Temporary Impairment Loss DebtAndEquitySecuritiesGainLossExcludingOtherThanTemporaryImpairmentLoss	12300000	USD
	us-gaap	Debt And Equity Securities Gain Loss Excluding Other Than Temporary Impairment Loss DebtAndEquitySecuritiesGainLossExcludingOtherThanTemporaryImpairmentLoss	-24000000.0	USD
CY2021Q3	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	-1400000	USD
CY2020Q3	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	8100000	USD
	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	13900000	USD
	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	-31400000	USD
CY2021Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-2300000	USD
CY2020Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	16300000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	26200000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-55400000	USD
CY2021Q3	cno	Fee Revenue And Other Income FeeRevenueAndOtherIncome	31800000	USD
CY2020Q3	cno	Fee Revenue And Other Income FeeRevenueAndOtherIncome	25400000	USD
	cno	Fee Revenue And Other Income FeeRevenueAndOtherIncome	102100000	USD
	cno	Fee Revenue And Other Income FeeRevenueAndOtherIncome	86100000	USD
CY2021Q3	us-gaap	Revenues Revenues	968300000	USD
CY2020Q3	us-gaap	Revenues Revenues	1013500000	USD
	us-gaap	Revenues Revenues	3047400000	USD
	us-gaap	Revenues Revenues	2744900000	USD
CY2021Q3	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	524800000	USD
CY2020Q3	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	560700000	USD
	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	1641300000	USD
	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	1591800000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	23700000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	23700000	USD
	us-gaap	Interest Expense InterestExpense	71800000	USD
	us-gaap	Interest Expense InterestExpense	85500000	USD
CY2021Q3	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	57900000	USD
CY2020Q3	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	53500000	USD
	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	200200000	USD
	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	192200000	USD
CY2021Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	233900000	USD
CY2020Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	209200000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	714500000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	674600000	USD
CY2021Q3	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	840300000	USD
CY2020Q3	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	847100000	USD
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	2627800000	USD
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	2544100000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	128000000.0	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	166400000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	419600000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	200800000	USD
CY2021Q3	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	28200000	USD
CY2020Q3	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	37200000	USD
	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	94400000	USD
	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	44800000	USD
CY2021Q3	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	0	USD
	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	0	USD
	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-34000000.0	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	99800000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	129200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	325200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	190000000.0	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	126429000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	140900000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	130528000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	143384000	shares
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.79
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.92
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.49
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.33
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129018000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141730000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133162000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	144090000	shares
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.77
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.91
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.32
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	99800000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	129200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	325200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	190000000.0	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-112900000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	428400000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-436600000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	759200000	USD
CY2021Q3	cno	Other Comprehensive Income Loss Amortizationof Present Valueof Future Profitsand Deferred Acquisition Costs Unrealized Holding Gain Loss Arising During Periodbefore Tax OtherComprehensiveIncomeLossAmortizationofPresentValueofFutureProfitsandDeferredAcquisitionCostsUnrealizedHoldingGainLossArisingDuringPeriodbeforeTax	-13400000	USD
CY2020Q3	cno	Other Comprehensive Income Loss Amortizationof Present Valueof Future Profitsand Deferred Acquisition Costs Unrealized Holding Gain Loss Arising During Periodbefore Tax OtherComprehensiveIncomeLossAmortizationofPresentValueofFutureProfitsandDeferredAcquisitionCostsUnrealizedHoldingGainLossArisingDuringPeriodbeforeTax	59900000	USD
	cno	Other Comprehensive Income Loss Amortizationof Present Valueof Future Profitsand Deferred Acquisition Costs Unrealized Holding Gain Loss Arising During Periodbefore Tax OtherComprehensiveIncomeLossAmortizationofPresentValueofFutureProfitsandDeferredAcquisitionCostsUnrealizedHoldingGainLossArisingDuringPeriodbeforeTax	-21600000	USD
	cno	Other Comprehensive Income Loss Amortizationof Present Valueof Future Profitsand Deferred Acquisition Costs Unrealized Holding Gain Loss Arising During Periodbefore Tax OtherComprehensiveIncomeLossAmortizationofPresentValueofFutureProfitsandDeferredAcquisitionCostsUnrealizedHoldingGainLossArisingDuringPeriodbeforeTax	54600000	USD
CY2021Q3	cno	Other Comprehensive Income Loss Amortizationof Present Valueof Future Profitsand Deferred Acquisitions Costs Reductionin Premium Deficienciesbefore Tax OtherComprehensiveIncomeLossAmortizationofPresentValueofFutureProfitsandDeferredAcquisitionsCostsReductioninPremiumDeficienciesbeforeTax	16500000	USD
CY2020Q3	cno	Other Comprehensive Income Loss Amortizationof Present Valueof Future Profitsand Deferred Acquisitions Costs Reductionin Premium Deficienciesbefore Tax OtherComprehensiveIncomeLossAmortizationofPresentValueofFutureProfitsandDeferredAcquisitionsCostsReductioninPremiumDeficienciesbeforeTax	-1000000.0	USD
	cno	Other Comprehensive Income Loss Amortizationof Present Valueof Future Profitsand Deferred Acquisitions Costs Reductionin Premium Deficienciesbefore Tax OtherComprehensiveIncomeLossAmortizationofPresentValueofFutureProfitsandDeferredAcquisitionsCostsReductioninPremiumDeficienciesbeforeTax	114000000.0	USD
	cno	Other Comprehensive Income Loss Amortizationof Present Valueof Future Profitsand Deferred Acquisitions Costs Reductionin Premium Deficienciesbefore Tax OtherComprehensiveIncomeLossAmortizationofPresentValueofFutureProfitsandDeferredAcquisitionsCostsReductioninPremiumDeficienciesbeforeTax	-196000000.0	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	900000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	8500000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	26400000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	-41200000	USD
CY2021Q3	cno	Other Comprehensive Income Loss Reclassification Adjustment For Amortization Of Present Value Of Future Profits And Deferred Acquisition Costs Related To Net Realized Investment Gains Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForAmortizationOfPresentValueOfFutureProfitsAndDeferredAcquisitionCostsRelatedToNetRealizedInvestmentGainsBeforeTax	100000	USD
CY2020Q3	cno	Other Comprehensive Income Loss Reclassification Adjustment For Amortization Of Present Value Of Future Profits And Deferred Acquisition Costs Related To Net Realized Investment Gains Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForAmortizationOfPresentValueOfFutureProfitsAndDeferredAcquisitionCostsRelatedToNetRealizedInvestmentGainsBeforeTax	100000	USD
	cno	Other Comprehensive Income Loss Reclassification Adjustment For Amortization Of Present Value Of Future Profits And Deferred Acquisition Costs Related To Net Realized Investment Gains Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForAmortizationOfPresentValueOfFutureProfitsAndDeferredAcquisitionCostsRelatedToNetRealizedInvestmentGainsBeforeTax	1400000	USD
	cno	Other Comprehensive Income Loss Reclassification Adjustment For Amortization Of Present Value Of Future Profits And Deferred Acquisition Costs Related To Net Realized Investment Gains Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForAmortizationOfPresentValueOfFutureProfitsAndDeferredAcquisitionCostsRelatedToNetRealizedInvestmentGainsBeforeTax	-3000000.0	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-83800000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	359100000	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-326000000.0	USD
	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	546800000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-18000000.0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	77700000	USD
	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-69600000	USD
	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	117700000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-65800000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	281400000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-256400000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	429100000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	34000000.0	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	410600000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	68800000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	619100000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	4731200000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	129200000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	77700000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	281400000	USD
CY2020Q3	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	50000000.0	USD
CY2020Q3	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	17000000.0	USD
CY2020Q3	cno	Stock Based Compensation StockBasedCompensation	9100000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	5083900000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	5324000000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	99800000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-18000000.0	USD
CY2021Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-65800000	USD
CY2021Q3	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	115000000.0	USD
CY2021Q3	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	16600000	USD
CY2021Q3	cno	Stock Based Compensation StockBasedCompensation	6500000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	5232900000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	4677000000	USD
	us-gaap	Net Income Loss NetIncomeLoss	190000000.0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	117700000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	429100000	USD
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	163000000.0	USD
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	50400000	USD
	cno	Stock Based Compensation StockBasedCompensation	19000000.0	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	5083900000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	5484200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	325200000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-69600000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-256400000	USD
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	302400000	USD
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	50100000	USD
	cno	Stock Based Compensation StockBasedCompensation	32400000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	5232900000	USD
	us-gaap	Proceeds From Insurance Premiums Collected ProceedsFromInsurancePremiumsCollected	1756400000	USD
	us-gaap	Proceeds From Insurance Premiums Collected ProceedsFromInsurancePremiumsCollected	1747800000	USD
	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	793100000	USD
	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	805900000	USD
	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	104300000	USD
	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	86100000	USD
	cno	Insurance Policy Benefits InsurancePolicyBenefits	1247300000	USD
	cno	Insurance Policy Benefits InsurancePolicyBenefits	1195000000	USD
	us-gaap	Interest Paid Net InterestPaidNet	57400000	USD
	us-gaap	Interest Paid Net InterestPaidNet	76100000	USD
	cno	Policy Acquisition Costs PolicyAcquisitionCosts	213300000	USD
	cno	Policy Acquisition Costs PolicyAcquisitionCosts	201500000	USD
	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	685700000	USD
	us-gaap	Payments For Other Operating Activities PaymentsForOtherOperatingActivities	612400000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-28900000	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	13000000.0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	479000000.0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	541800000	USD
	cno	Sales Of Investments SalesOfInvestments	1419700000	USD
	cno	Sales Of Investments SalesOfInvestments	1163200000	USD
	cno	Maturities And Redemptions Of Investments MaturitiesAndRedemptionsOfInvestments	2237800000	USD
	cno	Maturities And Redemptions Of Investments MaturitiesAndRedemptionsOfInvestments	1502700000	USD
	cno	Purchases Of Investments PurchasesOfInvestments	4363800000	USD
	cno	Purchases Of Investments PurchasesOfInvestments	3086700000	USD
	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	-21100000	USD
	us-gaap	Proceeds From Payments For Trading Securities ProceedsFromPaymentsForTradingSecurities	16200000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	68000000.0	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	25200000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-795400000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-429800000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18600000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000000.0	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	307800000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	168200000	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	49900000	USD
	us-gaap	Payments Of Dividends PaymentsOfDividends	50400000	USD
	us-gaap	Proceeds From Annuities And Investment Certificates ProceedsFromAnnuitiesAndInvestmentCertificates	1379300000	USD
	us-gaap	Proceeds From Annuities And Investment Certificates ProceedsFromAnnuitiesAndInvestmentCertificates	1160100000	USD
	us-gaap	Repayments Of Annuities And Investment Certificates RepaymentsOfAnnuitiesAndInvestmentCertificates	999300000	USD
	us-gaap	Repayments Of Annuities And Investment Certificates RepaymentsOfAnnuitiesAndInvestmentCertificates	923600000	USD
	us-gaap	Proceeds From Federal Home Loan Bank Borrowings ProceedsFromFederalHomeLoanBankBorrowings	720800000	USD
	us-gaap	Proceeds From Federal Home Loan Bank Borrowings ProceedsFromFederalHomeLoanBankBorrowings	190300000	USD
	us-gaap	Repayments Of Federal Home Loan Bank Borrowings RepaymentsOfFederalHomeLoanBankBorrowings	622100000	USD
	us-gaap	Repayments Of Federal Home Loan Bank Borrowings RepaymentsOfFederalHomeLoanBankBorrowings	191700000	USD
	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntities	1600000	USD
	cno	Repayments Of Investment Borrowings Related To Variable Interest Entities RepaymentsOfInvestmentBorrowingsRelatedToVariableInterestEntities	1600000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	900000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	137100000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19900000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-179300000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	131900000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	991900000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	654700000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	812600000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	786600000	USD
CY2021Q3	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments Having No Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsHavingNoAllowanceForCreditLosses	3017100000	USD
CY2020Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments Having No Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsHavingNoAllowanceForCreditLosses	3466300000	USD
CY2021Q3	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments With Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsWithAllowanceForCreditLosses	-23800000	USD
CY2020Q4	cno	Accumulated Other Comprehensive Income Loss Net Unrealized Appreciation On Investments With Allowance For Credit Losses AccumulatedOtherComprehensiveIncomeLossNetUnrealizedAppreciationOnInvestmentsWithAllowanceForCreditLosses	-10000000.0	USD
CY2021Q3	cno	Accumulated Other Comprehensive Income Loss Adjustment To Present Value Of Future Profits AccumulatedOtherComprehensiveIncomeLossAdjustmentToPresentValueOfFutureProfits	-8700000	USD
CY2020Q4	cno	Accumulated Other Comprehensive Income Loss Adjustment To Present Value Of Future Profits AccumulatedOtherComprehensiveIncomeLossAdjustmentToPresentValueOfFutureProfits	-10200000	USD
CY2021Q3	cno	Accumulated Other Comprehensive Income Loss Adjustment To Deferred Policy Acquisition Costs AccumulatedOtherComprehensiveIncomeLossAdjustmentToDeferredPolicyAcquisitionCosts	-438100000	USD
CY2020Q4	cno	Accumulated Other Comprehensive Income Loss Adjustment To Deferred Policy Acquisition Costs AccumulatedOtherComprehensiveIncomeLossAdjustmentToDeferredPolicyAcquisitionCosts	-458000000.0	USD
CY2021Q3	cno	Accumulated Other Comprehensive Income Adjustment To Insurance Liabilities Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized AccumulatedOtherComprehensiveIncomeAdjustmentToInsuranceLiabilitiesDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	-81900000	USD
CY2020Q4	cno	Accumulated Other Comprehensive Income Adjustment To Insurance Liabilities Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized AccumulatedOtherComprehensiveIncomeAdjustmentToInsuranceLiabilitiesDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	-197500000	USD
CY2021Q3	cno	Accumulated Other Comprehensive Income Loss Deferred Income Tax Liabilities AccumulatedOtherComprehensiveIncomeLossDeferredIncomeTaxLiabilities	-534900000	USD
CY2020Q4	cno	Accumulated Other Comprehensive Income Loss Deferred Income Tax Liabilities AccumulatedOtherComprehensiveIncomeLossDeferredIncomeTaxLiabilities	-604500000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1929700000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2186100000	USD
CY2021Q3	cno	Reduction To Present Value Of Future Profits Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized ReductionToPresentValueOfFutureProfitsDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	-7600000	USD
CY2021Q3	cno	Reduction To Deferred Acquisition Costs Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized ReductionToDeferredAcquisitionCostsDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	-136000000.0	USD
CY2021Q3	cno	Accumulated Other Comprehensive Income Adjustment To Insurance Liabilities Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized AccumulatedOtherComprehensiveIncomeAdjustmentToInsuranceLiabilitiesDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	-81900000	USD
CY2021Q3	cno	Increase To Deferred Tax Assets Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized IncreaseToDeferredTaxAssetsDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	48900000	USD
CY2020Q4	cno	Reduction To Present Value Of Future Profits Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized ReductionToPresentValueOfFutureProfitsDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	-8600000	USD
CY2020Q4	cno	Reduction To Deferred Acquisition Costs Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized ReductionToDeferredAcquisitionCostsDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	-133400000	USD
CY2020Q4	cno	Accumulated Other Comprehensive Income Adjustment To Insurance Liabilities Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized AccumulatedOtherComprehensiveIncomeAdjustmentToInsuranceLiabilitiesDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	-197500000	USD
CY2020Q4	cno	Increase To Deferred Tax Assets Due To Unrealized Gains That Would Result In Premium Deficiency If Unrealized Gains Were Realized IncreaseToDeferredTaxAssetsDueToUnrealizedGainsThatWouldResultInPremiumDeficiencyIfUnrealizedGainsWereRealized	73700000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	133800000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	135000000.0	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	1062600000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	1127600000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	1433200000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1568400000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	13167700000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	15633800000	USD
CY2021Q3	cno	Available For Sale Securities Debt Maturities Amortized Cost Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostExcludingStructuredSecurities	15797300000	USD
CY2021Q3	cno	Available For Sale Securities Debt Maturities Fair Value Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesFairValueExcludingStructuredSecurities	18464800000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost	5353700000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	5677200000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	21151000000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	24142000000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	388700000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	396400000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	987400000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	1052900000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	1540400000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1715600000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	11681000000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	14566500000	USD
CY2020Q4	cno	Available For Sale Securities Debt Maturities Amortized Cost Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostExcludingStructuredSecurities	14597500000	USD
CY2020Q4	cno	Available For Sale Securities Debt Maturities Fair Value Excluding Structured Securities AvailableForSaleSecuritiesDebtMaturitiesFairValueExcludingStructuredSecurities	17731400000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost	5323600000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	5652200000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	19921100000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	23383600000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	757200000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	5400000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	137500000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	2700000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	894700000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	8100000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	885000000.0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	16300000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	324800000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	7200000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	1209800000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	23500000	USD
CY2021Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	2300000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	2500000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Purchased With Credit Deterioration Increase DebtSecuritiesAvailableForSaleAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	700000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	100000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery	0	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossRecovery	0	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	5400000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	2200000	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	4500000	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Purchased With Credit Deterioration Increase DebtSecuritiesAvailableForSaleAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	-700000	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	600000	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery	0	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	1200000	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossRecovery	0	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	5400000	USD
CY2020Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	10800000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	1800000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Purchased With Credit Deterioration Increase DebtSecuritiesAvailableForSaleAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	-4600000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Securities Sold DebtSecuritiesAvailableForSaleAllowanceForCreditLossSecuritiesSold	400000	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery	0	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossRecovery	0	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	7600000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	2100000	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded	25500000	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Purchased With Credit Deterioration Increase DebtSecuritiesAvailableForSaleAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Not To Sell Before Recovery Credit Loss Previously Recorded Expense Reversal DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotToSellBeforeRecoveryCreditLossPreviouslyRecordedExpenseReversal	-18800000	USD
	cno	Available For Sale Securities Value Of Securities Sold AvailableForSaleSecuritiesValueOfSecuritiesSold	350300000	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Sell Before Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossSellBeforeRecovery	0	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Writeoff DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff	0	USD
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Recovery DebtSecuritiesAvailableForSaleAllowanceForCreditLossRecovery	0	USD
CY2020Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Allowance For Credit Loss Excluding Accrued Interest DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest	7600000	USD
CY2021Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	8300000	USD
CY2020Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	11600000	USD
CY2021Q3	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-1000000.0	USD
CY2020Q3	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	600000	USD
CY2021Q3	us-gaap	Financing Receivable Allowance For Credit Loss Purchased With Credit Deterioration Increase FinancingReceivableAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	USD
CY2020Q3	us-gaap	Financing Receivable Allowance For Credit Loss Purchased With Credit Deterioration Increase FinancingReceivableAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	USD
CY2021Q3	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	0	USD
CY2020Q3	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	0	USD
CY2021Q3	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	0	USD
CY2020Q3	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	0	USD
CY2021Q3	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	7300000	USD
CY2020Q3	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	12200000	USD
CY2020Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	11800000	USD
	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-4500000	USD
	us-gaap	Financing Receivable Allowance For Credit Loss Purchased With Credit Deterioration Increase FinancingReceivableAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	USD
	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	0	USD
	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	0	USD
CY2021Q3	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	7300000	USD
CY2019Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	6700000	USD
	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	5500000	USD
	us-gaap	Financing Receivable Allowance For Credit Loss Purchased With Credit Deterioration Increase FinancingReceivableAllowanceForCreditLossPurchasedWithCreditDeteriorationIncrease	0	USD
	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	0	USD
	us-gaap	Financing Receivable Allowance For Credit Losses Recovery FinancingReceivableAllowanceForCreditLossesRecovery	0	USD
CY2020Q3	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	12200000	USD
CY2021Q3	cno	Other Investments Allowance For Credit Loss Period Increase Decrease OtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	1700000	USD
CY2020Q3	cno	Other Investments Allowance For Credit Loss Period Increase Decrease OtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	5000000.0	USD
	cno	Other Investments Allowance For Credit Loss Period Increase Decrease OtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	17100000	USD
	cno	Other Investments Allowance For Credit Loss Period Increase Decrease OtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	-17800000	USD
CY2021Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	-2300000	USD
CY2020Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	16300000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	26200000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-55400000	USD
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-2600000	USD
	us-gaap	Increase Decrease In Equity Securities Fv Ni IncreaseDecreaseInEquitySecuritiesFvNi	-6100000	USD
CY2021Q3	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	700000	USD
	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	12600000	USD
CY2020Q3	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	5600000	USD
	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-12300000	USD
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-200000	USD
	us-gaap	Increase Decrease In Debt Securities Trading IncreaseDecreaseInDebtSecuritiesTrading	-1200000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	26200000	USD
	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	13900000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-55400000	USD
	cno	Debt Securities Available For Sale And Other Investments Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAndOtherInvestmentsAllowanceForCreditLossPeriodIncreaseDecrease	-31400000	USD
CY2021Q3	cno	Numberof Investmentsin Defaultor Considered Nonperforming NumberofInvestmentsinDefaultorConsideredNonperforming	0	investment
	cno	Available For Sale Securities Value Of Securities Sold AvailableForSaleSecuritiesValueOfSecuritiesSold	412900000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	99800000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	129200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	325200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	190000000.0	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	126429000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	140900000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	130528000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	143384000	shares
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2589000	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	830000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2634000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	706000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	129018000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	141730000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	133162000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	144090000	shares
	cno	Numberof Product Lines NumberofProductLines	3	product_line
CY2021Q3	cno	Segment Revenues SegmentRevenues	964400000	USD
CY2020Q3	cno	Segment Revenues SegmentRevenues	983600000	USD
	cno	Segment Revenues SegmentRevenues	3000900000	USD
	cno	Segment Revenues SegmentRevenues	2757800000	USD
CY2021Q3	cno	Segment Expenses SegmentExpenses	845100000	USD
CY2020Q3	cno	Segment Expenses SegmentExpenses	838300000	USD
	cno	Segment Expenses SegmentExpenses	2669100000	USD
	cno	Segment Expenses SegmentExpenses	2404800000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	119300000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	145300000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	331800000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	353000000.0	USD
CY2021Q3	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	26500000	USD
CY2020Q3	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	32700000	USD
	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	74700000	USD
	cno	Income Tax Benefit On Operating Income Loss IncomeTaxBenefitOnOperatingIncomeLoss	76700000	USD
CY2021Q3	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	92800000	USD
CY2020Q3	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	112600000	USD
	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	257100000	USD
	cno	Operating Income Loss Net Of Tax OperatingIncomeLossNetOfTax	276300000	USD
CY2021Q3	us-gaap	Revenues Revenues	968300000	USD
CY2020Q3	us-gaap	Revenues Revenues	1013500000	USD
	us-gaap	Revenues Revenues	3047400000	USD
	us-gaap	Revenues Revenues	2744900000	USD
CY2021Q3	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	840300000	USD
CY2020Q3	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	847100000	USD
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	2627800000	USD
	us-gaap	Benefits Losses And Expenses BenefitsLossesAndExpenses	2544100000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	128000000.0	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	166400000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	419600000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	200800000	USD
CY2021Q3	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	28200000	USD
CY2020Q3	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	37200000	USD
	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	94400000	USD
	cno	Income Tax Expense Benefit Before Valuation Allowance Adjustment IncomeTaxExpenseBenefitBeforeValuationAllowanceAdjustment	44800000	USD
CY2021Q3	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	0	USD
	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	0	USD
	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-34000000.0	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	99800000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	129200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	325200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	190000000.0	USD
CY2021Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Net EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet	104000000	USD
CY2021Q3	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	29300000	USD
CY2020Q3	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	51800000	USD
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	250500000	USD
	us-gaap	Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet	-19600000	USD
CY2021Q3	us-gaap	Ceded Premiums Written CededPremiumsWritten	54300000	USD
CY2020Q3	us-gaap	Ceded Premiums Written CededPremiumsWritten	77200000	USD
	us-gaap	Ceded Premiums Written CededPremiumsWritten	163300000	USD
	us-gaap	Ceded Premiums Written CededPremiumsWritten	203000000	USD
CY2021Q3	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	76500000	USD
CY2020Q3	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	97600000	USD
	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	232900000	USD
	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	239800000	USD
CY2021Q3	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	5100000	USD
CY2020Q3	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	5700000	USD
	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	15400000	USD
	us-gaap	Assumed Premiums Written AssumedPremiumsWritten	17500000	USD
CY2021Q3	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	6400000	USD
CY2020Q3	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	9000000	USD
	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	21700000	USD
	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	24600000	USD
CY2021Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	14100000	USD
CY2020Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7400000	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	50900000	USD
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-44500000	USD
CY2021Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	14100000	USD
CY2020Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	29800000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	43500000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	89300000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	28200000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	37200000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	94400000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	44800000	USD
CY2021Q3	cno	Income Tax Expense Benefit Net Operating Loss Cares Act IncomeTaxExpenseBenefitNetOperatingLossCARESAct	0	USD
CY2020Q3	cno	Income Tax Expense Benefit Net Operating Loss Cares Act IncomeTaxExpenseBenefitNetOperatingLossCARESAct	0	USD
	cno	Income Tax Expense Benefit Net Operating Loss Cares Act IncomeTaxExpenseBenefitNetOperatingLossCARESAct	0	USD
	cno	Income Tax Expense Benefit Net Operating Loss Cares Act IncomeTaxExpenseBenefitNetOperatingLossCARESAct	-34000000.0	USD
CY2021Q3	cno	Income Tax Expense Benefit Total IncomeTaxExpenseBenefitTotal	28200000	USD
CY2020Q3	cno	Income Tax Expense Benefit Total IncomeTaxExpenseBenefitTotal	37200000	USD
	cno	Income Tax Expense Benefit Total IncomeTaxExpenseBenefitTotal	94400000	USD
	cno	Income Tax Expense Benefit Total IncomeTaxExpenseBenefitTotal	10800000	USD
	cno	Income Tax Expense Benefit Net Operating Loss Cares Act IncomeTaxExpenseBenefitNetOperatingLossCARESAct	-34000000	USD
CY2021Q3	cno	Income Taxes Receivable Net Operating Loss Cares Act IncomeTaxesReceivableNetOperatingLossCARESAct	80000000	USD
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.001
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.005
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.016
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.018
	cno	Effective Income Tax Rate Reconciliation Before Discrete Items Percent EffectiveIncomeTaxRateReconciliationBeforeDiscreteItemsPercent	0.225
	cno	Effective Income Tax Rate Reconciliation Before Discrete Items Percent EffectiveIncomeTaxRateReconciliationBeforeDiscreteItemsPercent	0.223
	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.169
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.225
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.054
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	265400000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	339200000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	1500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2700000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	389500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Policyholder Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsPolicyholderLiabilities	386400000	USD
CY2021Q3	cno	Deferred Tax Assets Indirect Costs Allocableto Self Constructed Real Estate Assets DeferredTaxAssetsIndirectCostsAllocabletoSelfConstructedRealEstateAssets	142500000	USD
CY2020Q4	cno	Deferred Tax Assets Indirect Costs Allocableto Self Constructed Real Estate Assets DeferredTaxAssetsIndirectCostsAllocabletoSelfConstructedRealEstateAssets	105700000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	31600000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	43000000.0	USD
CY2021Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	830500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	877000000.0	USD
CY2021Q3	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	40500000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	29500000	USD
CY2021Q3	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	122300000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Policy Acquisition Cost DeferredTaxLiabilitiesDeferredExpenseDeferredPolicyAcquisitionCost	133800000	USD
CY2021Q3	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	532200000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	604300000	USD
CY2021Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	695000000.0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	767600000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	135500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	109400000	USD
CY2021Q3	cno	Prepaid Accrued Income Taxes Current PrepaidAccruedIncomeTaxesCurrent	10200000	USD
CY2020Q4	cno	Prepaid Accrued Income Taxes Current PrepaidAccruedIncomeTaxesCurrent	90000000.0	USD
CY2021Q3	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	145700000	USD
CY2020Q4	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	199400000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	135500000	USD
CY2021Q3	cno	Loss Limitation Based On Income Of Life Insurance Company LossLimitationBasedOnIncomeOfLifeInsuranceCompany	0.35
CY2021Q3	cno	Loss Limitation Based On Loss Of Non Life Entities LossLimitationBasedOnLossOfNonLifeEntities	0.35
CY2021Q3	cno	Federal Long Term Tax Exempt Rate FederalLongTermTaxExemptRate	0.0157
CY2021Q3	cno	Ownership Change Threshold Restricting Net Operating Loss Usage OwnershipChangeThresholdRestrictingNetOperatingLossUsage	0.50
CY2021Q3	cno	Nonoperating Loss Carryforwards NonoperatingLossCarryforwards	1263600000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	1500000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2700000	USD
CY2021Q3	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	13000000.0	USD
CY2020Q4	us-gaap	Deferred Finance Costs Noncurrent Gross DeferredFinanceCostsNoncurrentGross	13800000	USD
CY2021Q3	us-gaap	Notes Payable NotesPayable	1137000000	USD
CY2020Q4	us-gaap	Notes Payable NotesPayable	1136200000	USD
	cno	Number Of Insurance Subsidiaries That Are Members Of The Federal Home Loan Bank NumberOfInsuranceSubsidiariesThatAreMembersOfTheFederalHomeLoanBank	3	subsidiary
	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	302400000	USD
CY2021Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	500000000	USD
CY2021Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	466900000	USD
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	50100000	USD
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.38
CY2021Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.13
	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.12
	us-gaap	Deferred Sales Inducements Additions DeferredSalesInducementsAdditions	12200000	USD
	us-gaap	Deferred Sales Inducements Additions DeferredSalesInducementsAdditions	10200000	USD
	us-gaap	Deferred Sales Inducements Amortization Expense DeferredSalesInducementsAmortizationExpense	10200000	USD
	us-gaap	Deferred Sales Inducements Amortization Expense DeferredSalesInducementsAmortizationExpense	10900000	USD
CY2021Q3	us-gaap	Deferred Sales Inducements Net DeferredSalesInducementsNet	61400000	USD
CY2020Q4	us-gaap	Deferred Sales Inducements Net DeferredSalesInducementsNet	59400000	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	21293100000	USD
CY2020Q1	us-gaap	Notes Receivable Net NotesReceivableNet	1559400000	USD
CY2020Q1	cno	Investments Held By Variable Interest Entities InvestmentsHeldByVariableInterestEntities	1178700000	USD
CY2020Q1	cno	Deferred Income Tax Assets Net Including Netof Current Income Tax Payable DeferredIncomeTaxAssetsNetIncludingNetofCurrentIncomeTaxPayable	437500000	USD
CY2020Q1	us-gaap	Reinsurance Recoverables On Paid Losses ReinsuranceRecoverablesOnPaidLosses	4781700000	USD
CY2020Q1	us-gaap	Assets Assets	33613100000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	517900000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	4659200000	USD
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LITIGATION AND OTHER LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are involved in various legal actions in the normal course of business, in which claims for compensatory and punitive damages are asserted, some for substantial amounts. We recognize an estimated loss from these loss contingencies when we believe it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Some of the pending matters have been filed as purported class actions and some actions have been filed in certain jurisdictions that permit punitive damage awards that are disproportionate to the actual damages incurred. The amounts sought in certain of these actions are often large or indeterminate and the ultimate outcome of certain actions is difficult to predict. In the event of an adverse outcome in one or more of these matters, there is a possibility that the ultimate liability may be in excess of the liabilities we have established and could have a material adverse effect on our business, financial condition, results of operations and cash flows. In addition, the resolution of pending or future litigation may involve modifications to the terms of outstanding insurance policies or could impact the timing and amount of rate increases, which could adversely affect the future profitability of the related insurance policies. Based upon information presently available, and in light of legal, factual and other defenses available to the Company and its subsidiaries, the Company does not believe that it is probable that the ultimate liability from either pending or threatened legal actions, after consideration of existing loss provisions, will have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows. However, given the inherent difficulty in predicting the outcome of legal proceedings, there exists the possibility that such legal actions could have a material adverse effect on the Company's consolidated financial condition, operating results or cash flows.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the inherent difficulty of predicting litigation outcomes, particularly those that will be decided by a jury, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">some matters purport to seek substantial or an unspecified amount of damages for unsubstantiated conduct spanning several years based on complex legal theories and damages models. The alleged damages typically are indeterminate or not factually supported in the complaint, and, in any event, the Company's experience indicates that monetary demands for damages often bear little relation to the ultimate loss. In some cases, plaintiffs are seeking to certify classes in the litigation and class certification either has been denied or is pending and we have filed oppositions to class certification or sought to decertify a prior class certification. In addition, for many of these cases: (i) there is uncertainty as to the outcome of pending appeals or motions; (ii) there are significant factual issues to be resolved; and/or (iii) there are novel legal issues presented. Accordingly, the Company cannot reasonably estimate the possible loss or range of loss in excess of amounts accrued, if any, or predict the timing of the eventual resolution of these matters. The Company reviews these matters on an ongoing basis. When assessing reasonably possible and probable outcomes, the Company bases its assessment on the expected ultimate outcome following all appeals.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 9, 2019, Bankers Conseco Life Insurance Company ("BCLIC") and Washington National commenced an action entitled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> Bankers Conseco Life Insurance Company and Washington National Insurance Company v. Wilmington Trust, National Association</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, in the Supreme Court of the State of New York, County of New York, Commercial Division (the "Wilmington Action"). BCLIC and Washington National seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. In the Wilmington Action, BCLIC and Washington National assert claims against Wilmington Trust, National Association ("Wilmington") for breaching its express contractual obligations under four trust agreements pursuant to which Wilmington was the trustee in regard to trust assets ceded as part of reinsurance agreements with Beechwood Re Ltd. ("BRe"), as well as for breaching its fiduciary duties to BCLIC and Washington National. The Court granted Wilmington's motion to dismiss this litigation. BCLIC and Washington National appealed the Court's decision. On April 20, 2021, the New York Appellate Division of the Supreme Court, First Judicial Department unanimously reversed the trial court and reinstated breach of contract and breach of fiduciary claims against Wilmington. The Wilmington Action is currently pending in the Supreme Court of the State of New York, County of New York, Commercial Division. </span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2019, the Joint Official Liquidators of Platinum Partners Value Arbitrage Fund L.P. (in Official Liquidation) and Principal Growth Strategies, LLC, commenced suit against, among others, CNO Financial Group, Inc., BCLIC, Washington National and 40\|86 Advisors, Inc. (collectively, the "CNO Parties") in Delaware Chancery Court. Plaintiffs seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. Plaintiffs allege that the CNO Parties were unjustly enriched when they terminated BCLIC and Washington National's reinsurance agreements with BRe and recaptured assets from reinsurance trusts, in particular, Agera securities. Plaintiffs contend that the Agera securities were fraudulently transferred to the reinsurance trusts by other Platinum-related entities and they are seeking to claw back those Agera securities, or the value of those assets, from the CNO Parties. The CNO Parties are vigorously contesting the plaintiff's claims. The CNO Parties had removed the case to the United States District Court for the District of Delaware but on April 6, 2020, the District Court granted the plaintiff's motion to remand the case back to the Delaware Chancery Court. Plaintiffs have filed an Amended Complaint and the CNO Parties have moved to dismiss the Amended Complaint. The Delaware Chancery Court denied the CNO Parties’ motions to dismiss the Amended Complaint on the basis of forum non conveniens, but granted the CNO Parties’ motion to stay the case pending the conclusion of a related matter. After the stay is lifted, the court will address the CNO Parties’ and other defendants’ motions to dismiss the Amended Complaint on numerous other grounds.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 28, 2019, BCLIC and Washington National commenced an action entitled Bankers Conseco Life Insurance Company and Washington National Insurance Company v. KPMG LLP, in the Supreme Court of the State of New York, County of New York, Commercial Division (the "KPMG Action"). BCLIC and Washington National seek an unspecified amount of damages, costs, attorney's fees, and other relief as the court deems appropriate. In the KPMG Action, BCLIC and Washington National assert claims against KPMG LLP ("KPMG") for aiding and abetting fraud, constructive fraud and negligent misrepresentation arising from KPMG's alleged role in the Platinum Partners' scheme to defraud BCLIC and Washington National into reinsuring its long-term care business with BRe. The Court granted KPMG’s motion to dismiss this litigation. BCLIC and Washington National appealed the Court's decision. On December 1, 2020, the New York Appellate Division of the Supreme Court, First Judicial Department unanimously reversed the trial court and reinstated the aiding and abetting claim against KPMG. The KPMG Action is currently pending in the Supreme Court of the State of New York, County of New York, Commercial Division.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Examinations and Fines</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance companies face significant risks related to regulatory investigations and actions. Regulatory investigations generally result from matters related to sales or underwriting practices, payment of contingent or other sales commissions, claim </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments and procedures, product design, product disclosure, additional premium charges for premiums paid on a periodic basis, denial or delay of benefits, charging excessive or impermissible fees on products, procedures related to canceling policies, changing the way cost of insurance charges are calculated for certain life insurance products or recommending unsuitable products to customers. We are, in the ordinary course of our business, subject to various examinations, inquiries and information requests from state, federal and other authorities. The ultimate outcome of these regulatory actions (including the costs of complying with information requests and policy reviews) cannot be predicted with certainty. In the event of an unfavorable outcome in one or more of these matters, the ultimate liability may be in excess of liabilities we have established and we could suffer significant reputational harm as a result of these matters, which could also have a material adverse effect on our business, financial condition, results of operations or cash flows.</span></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2011, we were notified of an examination to be done on behalf of a number of states for the purpose of determining compliance with unclaimed property laws by the Company and its subsidiaries. Such examination has included inquiries related to the use of data available on the U.S. Social Security Administration's Death Master File ("SSADMF") to identify instances where benefits under life insurance policies, annuities and retained asset accounts are payable. We are continuing to provide information to the examiners in response to their requests. A total of 41 states and the District of Columbia participated in this examination. In November 2018, we entered into a Global Resolution Agreement for compliance with laws and regulations concerning the identification, reporting and escheatment of unclaimed contract benefits or abandoned funds. Under the terms of the Global Resolution Agreement, a third-party auditor acting on behalf of the signatory jurisdictions is comparing expanded matching criteria to the SSADMF to identify deceased insureds and contract holders where a valid claim has not been made.</span></div>
	cno	Number Of States Participating In Examination Of Compliance With Unclaimed Property Laws NumberOfStatesParticipatingInExaminationOfComplianceWithUnclaimedPropertyLaws	41	state
	us-gaap	Net Income Loss NetIncomeLoss	325200000	USD
	us-gaap	Net Income Loss NetIncomeLoss	190000000.0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	227300000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	218800000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	123300000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-2300000	USD
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	255200000	USD
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	263900000	USD
	cno	Change In Accrued Investment Income Amortization Of Premium Or Discount On Investments And Fair Value Of Investments ChangeInAccruedInvestmentIncomeAmortizationOfPremiumOrDiscountOnInvestmentsAndFairValueOfInvestments	-232500000	USD
	cno	Change In Accrued Investment Income Amortization Of Premium Or Discount On Investments And Fair Value Of Investments ChangeInAccruedInvestmentIncomeAmortizationOfPremiumOrDiscountOnInvestmentsAndFairValueOfInvestments	-26000000.0	USD
	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	213300000	USD
	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	201500000	USD
	cno	Gain Losson Investments Excluding Cash Expenses GainLossonInvestmentsExcludingCashExpenses	26200000	USD
	cno	Gain Losson Investments Excluding Cash Expenses GainLossonInvestmentsExcludingCashExpenses	-55400000	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	20000000.0	USD
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	43500000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	479000000.0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	541800000	USD
	cno	Share Based Compensation Noncash Portion ShareBasedCompensationNoncashPortion	19200000	USD
	cno	Share Based Compensation Noncash Portion ShareBasedCompensationNoncashPortion	17500000	USD
CY2021Q3	cno	Variable Interest Entity Amortized Cost Securities Held VariableInterestEntityAmortizedCostSecuritiesHeld	1225300000	USD
CY2021Q3	cno	Variable Interest Entity Gross Unrealized Gains Fixed Maturity Securities VariableInterestEntityGrossUnrealizedGainsFixedMaturitySecurities	3200000	USD
CY2021Q3	cno	Variable Interest Entity Gross Unrealized Losses Fixed Maturity Securities VariableInterestEntityGrossUnrealizedLossesFixedMaturitySecurities	4700000	USD
CY2021Q3	cno	Variable Interest Entity Fixed Maturity Securities Allowance For Credit Loss VariableInterestEntityFixedMaturitySecuritiesAllowanceForCreditLoss	2500000	USD
CY2021Q3	cno	Variable Interest Entity Fixed Maturity Securities Fair Value VariableInterestEntityFixedMaturitySecuritiesFairValue	1221300000	USD
	cno	Variable Interest Entities Net Realized Gain Loss On Investments VariableInterestEntitiesNetRealizedGainLossOnInvestments	5100000	USD
	cno	Variable Interest Entities Net Gain Loss From Sale Of Fixed Maturity Investments VariableInterestEntitiesNetGainLossFromSaleOfFixedMaturityInvestments	7500000	USD
	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	12600000	USD
	cno	Variable Interest Entity Investments Gross Investment Losses From Sale Before Tax VariableInterestEntityInvestmentsGrossInvestmentLossesFromSaleBeforeTax	7700000	USD
	cno	Variable Interest Entities Investments Sold VariableInterestEntitiesInvestmentsSold	56100000	USD
	cno	Variable Interest Entities Net Realized Gain Loss On Investments VariableInterestEntitiesNetRealizedGainLossOnInvestments	-17900000	USD
	cno	Variable Interest Entities Net Gain Loss From Sale Of Fixed Maturity Investments VariableInterestEntitiesNetGainLossFromSaleOfFixedMaturityInvestments	5600000	USD
	cno	Variable Interest Entities Change In Allowance For Current Expected Credit Losses VariableInterestEntitiesChangeInAllowanceForCurrentExpectedCreditLosses	-12300000	USD
	cno	Variable Interest Entity Investments Gross Investment Losses From Sale Before Tax VariableInterestEntityInvestmentsGrossInvestmentLossesFromSaleBeforeTax	5700000	USD
	cno	Variable Interest Entities Investments Sold VariableInterestEntitiesInvestmentsSold	47300000	USD
CY2021Q3	cno	Number Of Investments Held By Variable Interest Entities In Default NumberOfInvestmentsHeldByVariableInterestEntitiesInDefault	0	investment
CY2021Q3	cno	Investments Held In Limited Partnerships InvestmentsHeldInLimitedPartnerships	593900000	USD
CY2021Q3	cno	Unfunded Commitmentsto Limited Partnerships UnfundedCommitmentstoLimitedPartnerships	234700000	USD
	cno	Fair Value Fixed Maturity Securities Valued Using Broker Quotes Percentage FairValueFixedMaturitySecuritiesValuedUsingBrokerQuotesPercentage	0.83
CY2021Q3	cno	Available For Sale Fixed Maturities With Significant Unobservable Inputs Investment Grade Percent AvailableForSaleFixedMaturitiesWithSignificantUnobservableInputsInvestmentGradePercent	0.84
CY2021Q3	cno	Available For Sale Maturities With Significant Unobservable Inputs Corporate Securities Percent AvailableForSaleMaturitiesWithSignificantUnobservableInputsCorporateSecuritiesPercent	0.71

Files In Submission

Name	View Source	Status
0001224608-21-000042-index-headers.html	Edgar Link	pending
0001224608-21-000042-index.html	Edgar Link	pending
0001224608-21-000042.txt	Edgar Link	pending
0001224608-21-000042-xbrl.zip	Edgar Link	pending
cno-20210930.htm	Edgar Link	pending
cno-20210930.xsd	Edgar Link	pending
cno-20210930_cal.xml	Edgar Link	unprocessable
cno-20210930_def.xml	Edgar Link	unprocessable
cno-20210930_htm.xml	Edgar Link	completed
cno-20210930_lab.xml	Edgar Link	unprocessable
cno-20210930_pre.xml	Edgar Link	unprocessable
cno09302021ex311.htm	Edgar Link	pending
cno09302021ex312.htm	Edgar Link	pending
cno09302021ex321.htm	Edgar Link	pending
cno09302021ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNO
CNO Financial Group, Inc. Stock $cno

2021 Q4 Form 10-Q Financial Statement

#000122460821000042 Filed on November 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNO CNO Financial Group, Inc. Stock $cno

2021 Q4 Form 10-Q Financial Statement

#000122460821000042 Filed on November 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNO
CNO Financial Group, Inc. Stock $cno